Zusammenfassung
Die gastroösophageale Refluxkrankheit (GERD) ist eine häufige chronische Krankheit mit 2 Formen: einerseits geprägt durch typische Symptome wie Sodbrennen und saures Aufstoßen; andererseits vornehmlich durch atypische Symptome wie z. B. chronischer Husten, Heiserkeit, Halsschmerzen, Globussensationen im Hals, Zungenbrennen, rezidivierende Sinusitiden, Asthma bronchiale, dentale Erosionen, retrosternale Schmerzen oder Räusperzwang durch Schleimproduktion. Zur Standardtherapie gehört eine medikamentöse Säuresuppression durch Protonenpumpenhemmer. Viele Patienten, insbesondere die mit atypischen Beschwerden, sprechen jedoch nicht adäquat auf die Therapie an. Erst nach sicherer Identifikation der GERD-Patienten durch eine valide Diagnostik kann eine modifizierte pharmakologische oder interventionelle Therapie individualisiert werden. Können atypische GERD-Symptome nicht objektiviert werden, liegt eher keine GERD vor. Andere Ursachen der Symptome müssen dann in Erwägung gezogen und behandelt werden.
Abstract
Gastroesophageal reflux disease (GERD) is a frequent chronic disorder occurring in two forms: on the one hand, typical symptoms such as heartburn and acid regurgitation are seen, while on the other hand atypical (extraesophageal) symptoms such as chronic cough, hoarseness, recurrent sinusitis, globus sensations in the throat, a burning feeling on the tongue, dental erosions and the constant need to clear the throat can be associated with gastroesophageal reflux. The standard therapeutic medical procedure comprises the administration of acid-suppressive agents, proton pump inhibitors (PPI). However, this therapy has proved to be ineffective in a number of patients, especially in atypical GERD. Only after reliable identification of the GERD patient by using valid diagnostic tools medical or interventional therapeutic options can be applied individually. In the absence of atypical GERD symptoms, the diagnosis of GERD becomes very unlikely and other causes of the symptoms need to be taken into consideration.
Literatur
Altman KW, Waltonen JD, Hammer ND et al (2005) Proton pump (H +/K + -ATPase) expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg 133(5):718–724
Agrawal A, Roberts J, Sharma N et al (2009) Symptoms with acid and nonacid reflux may be produced by different mechanisms. Dis Esophagus 22:467–470
Akbayir N, Sökmen HM, Caliş AB et al (2005) Heterotopic gastric mucosa in the cervical esophagus: could this play a role in the pathogenesis of laryngopharyngeal reflux in a subgroup of patients with posterior laryngitis? Scand J Gastroenterol 40:1149–1156
Babaei A, Bhargava V, Aalam S et al (2009) Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging. Aliment Pharmacol Ther 29:863–870
Bajbouj M, Becker V, Neuber M et al (2007) Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. Digestion 76:223–228
Bajbouj M, Becker V, Phillip V et al (2009) High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease–a prospective pH-metry/impedance-controlled study. Digestion 80:112–118
Bajbouj M, Becker V, Eckel F et al (2009) Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. Gastroenterology 137:440–444
Boeckxstaens GE (2008) Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 8:685–689
Boeckxstaens GE, Beaumont H, Hatlebakk JG et al (2011) A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut: (in press)
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798–1810
Fass R (2009) Proton pump inhibitor failure–what are the therapeutic options? Am J Gastroenterol 104:33–38
Friedman M, Maley A, Kelley K et al (2011) Impact of pH monitoring on laryngopharyngeal reflux treatment: improved compliance and symptom resolution. Otolaryngol Head Neck Surg 144(4):558–562
Gasiorowska A, Fass R (2008) The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol 42:867–874
Hicks DM, Ours TM, Abelson TI et al (2002) The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 16:564–579
Kahrilas PJ, Shaheen NJ, Vaezi MF (2008) Technical review on the management of gastroesophageal reflux disease. Gastroenterology 135:1392–1413
Koek GH, Sifrim D, Lerut T et al (2003) Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52:1397–402
Koufman JA, Aviv JE, Casiano RR, Shaw GY (2002) Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 127:32–35
Louis E, Jorissen P, Bastens B et al (2006) Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40 mg esomeprazole for one month. Acta Gastroenterol Belg 69:203–208
Malcomson KG (1968) Globus hystericus vel pharyngis. J Laryngol Otol 82(3):219–230
Meining A, Bajbouj M (2006a) Endoscopic anti reflux treatment–unhappy ending or start of a new era? Z Gastroenterol 44:943–944
Meining A, Bajbouj M, Preeg M et al (2006b) Argon plasma ablation of gastric inlet patches in the cervical esophagus may alleviate globus sensation: a pilot trial. Endoscopy 38:566–570
Poyrazoglu OK, Bahcecioglu IH, Dagli AF et al (2009) Heterotopic gastric mucosa (inlet patch): endoscopic prevalence, histopathological, demographical and clinical characteristics. Int J Clin Pract 63:287–291
Reichel O, Issing WJ (2008) Impact of different pH thresholds for 24-hour dual probe pH monitoring in patients with suspected laryngopharyngeal reflux. J Laryngol Otol 122:485–489
Rosanowski F, Rabenstein T, Hahn EG, Eysholdt U (2001) Reflux-associated diseases of the otorhinolaryngology tract. Laryngorhinootologie 80(8):487–496
Sifrim D, Silny J, Holloway RH, Janssens JJ (1999) Patterns of gas and liquid reflux during transient lower oesophageal sphincter relaxation: a study using intraluminal electrical impedance. Gut 44:47–54
Steward DL, Wilson KM, Kelly DH et al (2004) Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 131:342–350
Sun G, Muddana S, Slaughter JC et al (2009) A new pH catheter for laryngopharyngeal reflux: normal values. Laryngoscope 119:1639–1643
Ulualp SO, Toohill RJ, Hoffmann R, Shaker R (1999) Possible relationship of gastroesophagopharyngeal acid reflux with pathogenesis of chronic sinusitis. Am J Rhinol 13:197–202
Vaezi MF, Richter JE, Stasney CR et al (2006) Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 116:254–260
Vakil N, Zanten SV van, Kahrilas P et al (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: PD Dr. M. Bajbouj war als Referent für die Fa. Neuwirth Medical Products (Vertreiber der Restech®-Sonde) tätig.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bajbouj, M. Diagnostik und Therapie atypischer Refluxsymptome bei fehlendem PPI-Ansprechen. HNO 60, 193–199 (2012). https://doi.org/10.1007/s00106-011-2430-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-011-2430-9